Ginkgo Biloba P . E .
| Min. Order: | 25 Kilogram |
|---|---|
| Payment Terms: | T/T |
| Supply Ability: | 1000 |
| Place of Origin: | Shaanxi |
Company Profile
| Location: | China (Mainland) |
|---|---|
| Business Type: | Manufacturer |
Product Detail
| Model No.: | 24% |
|---|---|
| Means of Transport: | Air |
| Brand Name: | BThriving |
| Please input attribute name: | Please input the attribute value |
| Production Capacity: | 1000 |
| Packing: | 25kgs/drum |
| Delivery Date: | 15 work days |
Product Description
Ginkgo Biloba P . E .
Product Name: Ginkgo Biloba P.E.
Botanical Source: Ginkgo biloba L.
Used Part:Leaves
Assay:
Total Flavones 24% ,Total Lactones 6%, Total Ginkgolic Acid 5PPM
Appearance:Light Yellow Brown fine powder
Test method :HPLC
Function: Ginkgo biloba is commonly used in the treatment of early-stage Alzheimer's disease, vascular dementia, peripheral claudication,tinnitus of vascular origin, intermittent claudication, cerebrovascular disease, dementia, and memory enhancement .Studies also have shown positive results from the use of ginkgo for the following conditions: sexual dysfunction secondary to the use of selective serotonin reuptake inhibitors, 32 mountain sickness and decreasing vasoactivity in response to cold, 33 macular degeneration, 34 asthma, 35 and hypoxia. 36 The World Health Organization has recommended the use of ginkgo in Raynaud's disease, acrocyanosis, and post-phlebitic syndrome. 2,7
Product Name: Ginkgo Biloba P.E.
Botanical Source: Ginkgo biloba L.
Used Part:Leaves
Assay:
Total Flavones 24% ,Total Lactones 6%, Total Ginkgolic Acid 5PPM
Appearance:Light Yellow Brown fine powder
Test method :HPLC
Function: Ginkgo biloba is commonly used in the treatment of early-stage Alzheimer's disease, vascular dementia, peripheral claudication,tinnitus of vascular origin, intermittent claudication, cerebrovascular disease, dementia, and memory enhancement .Studies also have shown positive results from the use of ginkgo for the following conditions: sexual dysfunction secondary to the use of selective serotonin reuptake inhibitors, 32 mountain sickness and decreasing vasoactivity in response to cold, 33 macular degeneration, 34 asthma, 35 and hypoxia. 36 The World Health Organization has recommended the use of ginkgo in Raynaud's disease, acrocyanosis, and post-phlebitic syndrome. 2,7
